Collectively, these results demonstrate that TIGIT inhibition effectively restore and enhance NK cell cytotoxicity in DLBCL, potentially reversing tumor-mediated immune suppression and augmenting anti-tumor immunity. The gene discussed is TIGIT; the disease is diffuse large B-cell lymphoma.